NPCE Stock Overview
Operates as a medical device company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
NeuroPace, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.79 |
| 52 Week High | US$15.11 |
| 52 Week Low | US$5.45 |
| Beta | 2.04 |
| 1 Month Change | -10.07% |
| 3 Month Change | -14.32% |
| 1 Year Change | -15.18% |
| 3 Year Change | 84.22% |
| 5 Year Change | n/a |
| Change since IPO | -52.76% |
Recent News & Updates
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Mar 30 Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 07
Recent updates
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Mar 30 Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 07NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Jan 24After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
Dec 04Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
Nov 14Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Nov 07NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
Aug 03Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Apr 12NeuroPace: Picking Up The Pace
Feb 25Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Jan 22NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
Apr 17NeuroPace announces U.S. distribution agreement with DIXI Medical
Aug 11Shareholder Returns
| NPCE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.8% | -0.1% | 1.8% |
| 1Y | -15.2% | 6.3% | 9.5% |
Return vs Industry: NPCE underperformed the US Medical Equipment industry which returned 7.7% over the past year.
Return vs Market: NPCE underperformed the US Market which returned 9.6% over the past year.
Price Volatility
| NPCE volatility | |
|---|---|
| NPCE Average Weekly Movement | 9.3% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NPCE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NPCE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 184 | Joel Becker | www.neuropace.com |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
NeuroPace, Inc. Fundamentals Summary
| NPCE fundamental statistics | |
|---|---|
| Market cap | US$380.63m |
| Earnings (TTM) | -US$27.14m |
| Revenue (TTM) | US$79.91m |
4.8x
P/S Ratio-14.1x
P/E RatioIs NPCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPCE income statement (TTM) | |
|---|---|
| Revenue | US$79.91m |
| Cost of Revenue | US$20.82m |
| Gross Profit | US$59.09m |
| Other Expenses | US$86.23m |
| Earnings | -US$27.14m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 73.94% |
| Net Profit Margin | -33.97% |
| Debt/Equity Ratio | 742.9% |
How did NPCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/01 15:48 |
| End of Day Share Price | 2025/05/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroPace, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Rohin Patel | J.P. Morgan |